ijms-logo

Journal Browser

Journal Browser

New Technologies and Applications in Proteomics Research

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 2073

Special Issue Editor


E-Mail Website
Guest Editor
University of Texas Health Science Center at Houston, Houston, TX 77030, USA
Interests: cancer; Sjögrens syndrome; aging

Special Issue Information

Dear Colleagues,

Technological advancements in proteomic research have advanced to the point where many types of biological media are now assayed for minute protein concentrations at the femtomole level. This comprehensive analytical approach not only identifies disease biomarkers, but creates systems for new therapeutic agents as well as to reinforce the dynamic changes that give rise to cascades of new biomarkers for determining treatment efficacy. For example, the study of carcinoma can be employed as a model for how clinical proteomics is having an impact on early detection, rational therapeutic targeting, and tailored treatment regimens. Taken together, it is not sufficient to simply determine that the patient is in clinical remission; it is also necessary to determine if the patient is in molecular remission as well. Proteomics may allow us to make this significant determination a reality.

Prof. Dr. Charles Streckfus
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • proteomic
  • protein

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

28 pages, 6607 KiB  
Article
Morquio A Syndrome: Identification of Differential Patterns of Molecular Pathway Interactions in Bone Lesions
by J. Victor. Álvarez, Susana B. Bravo, María Pilar Chantada-Vázquez, Carmen Pena, Cristóbal Colón, Shunji Tomatsu, Francisco J. Otero-Espinar and María L. Couce
Int. J. Mol. Sci. 2024, 25(6), 3232; https://doi.org/10.3390/ijms25063232 - 12 Mar 2024
Viewed by 741
Abstract
Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) is a rare autosomal recessive lysosomal storage disease (LSD) caused by deficiency of a hydrolase enzyme, N-acetylgalactosamine-6-sulfate sulfatase, and characterized clinically by mainly musculoskeletal manifestations. The mechanisms underlying bone involvement in humans are typically explored [...] Read more.
Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) is a rare autosomal recessive lysosomal storage disease (LSD) caused by deficiency of a hydrolase enzyme, N-acetylgalactosamine-6-sulfate sulfatase, and characterized clinically by mainly musculoskeletal manifestations. The mechanisms underlying bone involvement in humans are typically explored using invasive techniques such as bone biopsy, which complicates analysis in humans. We compared bone proteomes using DDA and SWATH-MS in wild-type and MPS IVA knockout mice (UNT) to obtain mechanistic information about the disease. Our findings reveal over 1000 dysregulated proteins in knockout mice, including those implicated in oxidative phosphorylation, oxidative stress (reactive oxygen species), DNA damage, and iron transport, and suggest that lactate dehydrogenase may constitute a useful prognostic and follow-up biomarker. Identifying biomarkers that reflect MPS IVA clinical course, severity, and progression have important implications for disease management. Full article
(This article belongs to the Special Issue New Technologies and Applications in Proteomics Research)
Show Figures

Figure 1

15 pages, 5040 KiB  
Article
Integrated Analysis of Transcriptome and Proteome of the Human Cornea and Aqueous Humor Reveal Novel Biomarkers for Corneal Endothelial Cell Dysfunction
by Chae-Eun Moon, Chang Hwan Kim, Jae Hun Jung, Young Joo Cho, Kee Yong Choi, Kyusun Han, Kyoung Yul Seo, Hyung Keun Lee and Yong Woo Ji
Int. J. Mol. Sci. 2023, 24(20), 15354; https://doi.org/10.3390/ijms242015354 - 19 Oct 2023
Cited by 1 | Viewed by 1022
Abstract
Earlier studies have reported that elevated protein levels in the aqueous humor (AH) are associated with corneal endothelial cell dysfunction (CECD), but the details of the underlying mechanism as well as specific biomarkers for CECD remain elusive. In the present study, we aimed [...] Read more.
Earlier studies have reported that elevated protein levels in the aqueous humor (AH) are associated with corneal endothelial cell dysfunction (CECD), but the details of the underlying mechanism as well as specific biomarkers for CECD remain elusive. In the present study, we aimed to identify protein markers in AH directly associated with changes to corneal endothelial cells (CECs), as AH can be easily obtained for analysis. We carried out an in-depth proteomic analysis of patient-derived AH as well as transcriptomic analysis of CECs from the same patients with bullous keratopathy (BK) resulting from CECD. We first determined differentially expressed genes (DEGs) and differentially expressed proteins (DEPs) from CECs and AH in CECD, respectively. By combining transcriptomic and proteomic analyses, 13 shared upregulated markers and 22 shared downregulated markers were observed between DEGs and DEPs. Among these 35 candidates from biomarker profiling, three upregulated markers were finally verified via data-independent acquisition (DIA) proteomic analysis using additional individual AH samples, namely metallopeptidase inhibitor 1 (TIMP1), Fc fragment of IgG binding protein (FCGBP), and angiopoietin-related protein 7 (ANGPTL7). Furthermore, we confirmed these AH biomarkers for CECD using individual immunoassay validation. Conclusively, our findings may provide valuable insights into the disease process and identify biofluid markers for the assessment of CEC function during BK development. Full article
(This article belongs to the Special Issue New Technologies and Applications in Proteomics Research)
Show Figures

Figure 1

Back to TopTop